IHH Healthcare stock reports 30 percent PATMI growth in Q2

Published on 10/07/2026 at 03:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

IHH Healthcare stock posted a 23 percent Q2 core EBITDA margin in 2026, while guidance stayed at 22 percent to 24 percent. Bursa Malaysia shares were at MYR 7.74 on October 6.

IHH Healthcare, MYL5225OO007, Illustration mit AI erstellt.

IHH Healthcare stock was trading at MYR 7.74 on Bursa Malaysia on October 6, 2026, as the hospital operator entered the final quarter with Q2 PATMI excluding exceptional items up 30 percent year over year to MYR 675 million. The latest operating figures point to higher patient volumes, but the stock's valuation still depends on sustained execution across Singapore, Malaysia, India and Türkiye.

Q2 earnings reach MYR 675 million

According to Quartr in its Q2 2026 earnings summary, revenue reached MYR 7,046 million and EBITDA MYR 1,607 million. Revenue increased 12 percent year over year, while EBITDA rose 19 percent and PATMI excluding exceptional items climbed 30 percent.

The same Q2 2026 summary puts core EBITDA margin at 23 percent and core PATMI margin at 10 percent. Year-to-date 2026 revenue reached MYR 13,599 million, up 8 percent, while EBITDA stood at MYR 3,042 million, up 13 percent.

Margin guidance stays at 22 to 24 percent

IHH Healthcare maintained EBITDA margin guidance of 22 percent to 24 percent for the remainder of 2026, according to Yahoo Finance in the Q2 earnings call transcript. Management linked the performance to patient intensity and admissions, with Malaysia revenue and EBITDA growing 15 percent and 29 percent respectively on a constant-currency basis.

The operating mix also highlights the main execution issue. Singapore is recovering, while higher medical costs and the pace of patient-volume growth will determine whether fixed-cost leverage converts the current revenue expansion into wider margins.

Analysts see a higher valuation

The Edge Malaysia reported that RHB Research upgraded IHH to Buy from Neutral on September 7, 2026, raising its target price to MYR 9.54 from MYR 9.30 after first-half core earnings reached MYR 1 billion, up 22 percent year over year. The report said first-half net profit rose 14.9 percent to MYR 1.1 billion and revenue increased 8 percent to MYR 13.6 billion.

Consensus remains higher than the October 6 market price. Investing.com lists a Strong Buy rating from 23 analysts, including 22 Buy ratings and 1 Hold, with an average 12-month target of MYR 10.22, a high of MYR 11.43 and a low of MYR 9.10. The average target lies 32.0 percent above MYR 7.74.

Stock trades at MYR 7.74

IHH Healthcare was trading at MYR 7.74 on Bursa Malaysia on October 6, 2026. The company had a market capitalization of MYR 69.4 billion as of October 5, 2026, giving investors a market-value benchmark alongside the Q2 earnings improvement.